GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sichuan Kelun Pharmaceutical Co Ltd (SZSE:002422) » Definitions » Beneish M-Score

Sichuan Kelun Pharmaceutical Co (SZSE:002422) Beneish M-Score : -2.59 (As of Mar. 26, 2025)


View and export this data going back to 2010. Start your Free Trial

What is Sichuan Kelun Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.59 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Sichuan Kelun Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

SZSE:002422' s Beneish M-Score Range Over the Past 10 Years
Min: -2.88   Med: -2.61   Max: -2.37
Current: -2.59

During the past 13 years, the highest Beneish M-Score of Sichuan Kelun Pharmaceutical Co was -2.37. The lowest was -2.88. And the median was -2.61.


Sichuan Kelun Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Sichuan Kelun Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun Pharmaceutical Co Beneish M-Score Chart

Sichuan Kelun Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.53 -2.63 -2.80 -2.50 -2.88

Sichuan Kelun Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.85 -2.88 -2.73 -2.63 -2.59

Competitive Comparison of Sichuan Kelun Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - General subindustry, Sichuan Kelun Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Kelun Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sichuan Kelun Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun Pharmaceutical Co's Beneish M-Score falls into.



Sichuan Kelun Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Sichuan Kelun Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9552+0.528 * 0.9921+0.404 * 0.8953+0.892 * 1.0796+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8805+4.679 * -0.036378-0.327 * 0.823
=-2.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was ¥6,589 Mil.
Revenue was 4961.673 + 5607.685 + 6219.417 + 5710.832 = ¥22,500 Mil.
Gross Profit was 2448.634 + 2894.008 + 3472.794 + 2915.014 = ¥11,730 Mil.
Total Current Assets was ¥19,066 Mil.
Total Assets was ¥38,392 Mil.
Property, Plant and Equipment(Net PPE) was ¥12,998 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥4,471 Mil.
Total Current Liabilities was ¥10,143 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,448 Mil.
Net Income was 670.816 + 773.923 + 1026.188 + 492.785 = ¥2,964 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 742.725 + 1253.936 + 1278.763 + 1084.918 = ¥4,360 Mil.
Total Receivables was ¥6,389 Mil.
Revenue was 4944.543 + 5160.691 + 5637.863 + 5098.2 = ¥20,841 Mil.
Gross Profit was 2593.072 + 2653.177 + 3087.131 + 2446.275 = ¥10,780 Mil.
Total Current Assets was ¥17,673 Mil.
Total Assets was ¥35,960 Mil.
Property, Plant and Equipment(Net PPE) was ¥11,666 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥4,703 Mil.
Total Current Liabilities was ¥9,537 Mil.
Long-Term Debt & Capital Lease Obligation was ¥3,653 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(6588.755 / 22499.607) / (6389.411 / 20841.297)
=0.292839 / 0.306575
=0.9552

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(10779.655 / 20841.297) / (11730.45 / 22499.607)
=0.517226 / 0.521362
=0.9921

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (19065.883 + 12998.045) / 38392.364) / (1 - (17673.464 + 11665.838) / 35959.92)
=0.164836 / 0.184111
=0.8953

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=22499.607 / 20841.297
=1.0796

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 11665.838)) / (0 / (0 + 12998.045))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(4470.695 / 22499.607) / (4703.239 / 20841.297)
=0.198701 / 0.225669
=0.8805

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1447.79 + 10142.721) / 38392.364) / ((3652.895 + 9537.321) / 35959.92)
=0.301896 / 0.366803
=0.823

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2963.712 - 0 - 4360.342) / 38392.364
=-0.036378

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Sichuan Kelun Pharmaceutical Co has a M-score of -2.59 suggests that the company is unlikely to be a manipulator.


Sichuan Kelun Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Kelun Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.36 West Baihua Road, Qingyang District, Chengdu, CHN, 610071
Sichuan Kelun Pharmaceutical Co Ltd is a China-based Pharmaceutical company mainly focused on the production and sales of injection products, including products for glucose injection and sodium chloride injection. It manufactures and sells high-volume injections (infusions), small-volume injections (water needles), sterile powder injections (containing powdered and freeze-dried powder). Its products include tablets, capsules, capsules, granules, oral liquids, peritoneal dialysis fluids, raw material medicines, medical packaging materials, medical instruments, and antibiotic intermediates.
Executives
Lai De Gui Executives
Feng Hao Directors, executives
Liu Si Chuan Directors, executives
Wang Jing Yi Directors, executives
Wan Yang Yu Executives
Ge Jun You Executives
Wu Zhong Hua Executives
Wan Peng Supervisors
Tan Hong Bo Executives
Liu Ge Xin Director
Huang Xin Securities Affairs Representative
Ge Tao Executives
Pan Hui Directors, executives
Zhou Xiao Dong Executives
Zheng Chang Yan Supervisors

Sichuan Kelun Pharmaceutical Co Headlines

No Headlines